Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | FDPS | P14324 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL27845326 | 0.90 | SMN1; SMN2 (0.50) | CYP1A2CYP2C9CYP2C19FDPSSMN1; SMN2 | |
| SCHEMBL28135896 | 0.87 | TAAR1 (0.47) | CYP1A2CYP2C9CYP2C19FDPSSMN1; SMN2 | |
| SCHEMBL28607388 | 0.85 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19FDPSSMN1; SMN2 | |
| SCHEMBL11106147 | 0.84 | TAAR1 (0.44) | CYP1A2CYP2C9CYP2C19FDPSSMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL4608399 | 0.82 | CYP1A2 (0.58) | CYP1A2CYP2C9CYP2C19FDPSSMN1; SMN2 | |
| SCHEMBL11106957 | 0.81 | TAAR1 (0.41) | CYP1A2CYP2C9CYP2C19FDPSSMN1; SMN2 | |
| SCHEMBL9271997 | 0.79 | TAAR1 (0.58) | CYP1A2CYP2C9CYP2C19FDPSSMN1; SMN2 | |
| SCHEMBL3273807 | 0.78 | CYP1A2 (0.54) | CYP1A2CYP2C9CYP2C19FDPSSMN1; SMN2 | |
| SCHEMBL7276106 | 0.77 | HTR2A (0.50) | CYP1A2CYP2C19FDPSSMN1; SMN2TAAR1 | |
| SCHEMBL21243974 | 0.77 | CYP1A2 (0.48) | CYP1A2CYP2C9CYP2C19FDPSSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115710464-A | Silicon oxide dielectric layer chemical mechanical polishing solution with low surface roughness | 博力思(天津)电子科技有限公司 | 2023-02-24 | — | — | CN | claimed |
| CN-115710464-A | Silicon oxide dielectric layer chemical mechanical polishing solution with low surface roughness | 博力思(天津)电子科技有限公司 | 2023-02-24 | — | — | CN | disclosed |
| CN-109096128-B | Preparation method of aminopolyethylene glycol propionic acid | 江苏金斯瑞生物科技有限公司 | 2021-03-09 | — | — | CN | disclosed |
| EP-3006437-B1 | (+)-5-(3,4-DIFLUOROPHENYL)-5-[(3-METHYL-2-OXOPYRIDIN-1(2H)-YL)METHYL]IMIDAZOLIDINE-2,4-DIONE AND DRUG CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| EP-2617812-B1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | UNIV TOKYO (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| EP-3009426-B1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | KAKEN PHARMA CO LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| EP-2789607-B1 | PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-9855257-B2 | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2018-01-02 | — | — | US | disclosed |
| US-20170128431-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2017-05-11 | — | — | US | disclosed |
| CN-101742909-A | Have purposes and weed killer herbicide and the algaecide composition of the compound of single galactosyl DG synthase inhibitory activity as weed killer herbicide or algicide | CENTRE NAT RECH SCIENT | 2010-06-16 | — | — | CN | disclosed |
| EP-2094079-A1 | COMPOSITION FOR REPELLING AND DETERRING VERMIN | Novartis Ag (CH) | 2009-09-02 | — | — | EP | disclosed |
| CN-101460468-A | 2-pyrazinecarboxamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-06-17 | — | — | CN | disclosed |
| US-7511144-B2 | Reverse hydroxamic acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| EP-1431285-B1 | REVERSE HYDROXAMIC ACID DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008062006-A1 | COMPOSITION FOR REPELLING AND DETERRING VERMIN | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | STUDOR S.A. (LU) | 2004-12-02 | — | — | US | disclosed |
| EP-1431285-A1 | REVERSE HYDROXAMIC ACID DERIVATIVES | Kaken Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-4353787-A | COATINGS, ADHESIVES, CASTINGS, REINFORCED COMPOSITES | SCOTT BADER COMPANY LIMITED (GB) | 1982-10-12 | — | — | US | disclosed |
| US-4226969-A | AMINE HARDENER, AMINOALCOHOL | ALLIED PRODUCTS CORPORATION (US) | 1980-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | PNPO, PDXK, PLPBP | CYP1A2 20/4885CYP2C9 34/4885CYP2C19 6/4885 |
| US-20170128431-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | PTGER4, IL4, PTGER1 | CYP1A2 469/4885CYP2C9 707/4885CYP2C19 209/4885 |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | TNF, RNASE1, IFNAR1 | CYP1A2 1130/4885CYP2C9 3181/4885CYP2C19 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.